Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$55.77 USD

55.77
722,002

+0.14 (0.25%)

Updated Jan 24, 2025 04:00 PM ET

After-Market: $55.75 -0.02 (-0.04%) 5:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.30%
2Buy18.13%
3Hold9.74%
4Sell5.28%
5Strong Sell2.72%
S&P50011.39%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for HALO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Assets          
Cash & Equivalents -99,999 336 363 741 368
Receivables NA 234 231 91 98
Notes Receivable NA 0 0 0 0
Inventories NA 128 100 54 61
Other Current Assets NA 49 45 40 28
Total Current Assets NA 746 739 926 555
Net Property & Equipment NA 75 76 9 11
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 4 44 155 0
Intangibles NA 890 956 0 0
Deposits & Other Assets NA 18 27 14 15
Total Assets NA 1,733 1,842 1,104 580
Liabilities & Shareholders Equity 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 12 18 2 2
Current Portion Long-Term Debt NA 0 13 89 397
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 101 97 24 20
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 3 2 2
Total Current Liabilities NA 112 131 117 421
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 2 3 4
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,499 1,493 787 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 38 46 1 3
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,649 1,672 907 429
Shareholders Equity 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2 27 256 625
Retained Earnings NA 91 143 -59 -475
Other Equity NA -9 -1 -1 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 84 170 197 151
Total Liabilities & Shareholder's Equity NA 1,733 1,842 1,104 580
Total Common Equity 0 84 170 197 151
Shares Outstanding 127.20 132.10 135.20 140.70 135.10
Book Value Per Share 0.00 0.63 1.26 1.40 1.12

Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023
Assets          
Cash & Equivalents -99,999 666 529 463 336
Receivables NA 286 215 196 234
Notes Receivable NA 0 0 0 0
Inventories NA 131 159 169 128
Other Current Assets NA 44 85 46 49
Total Current Assets NA 1,127 988 874 746
Net Property & Equipment NA 74 75 78 75
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 1 4
Intangibles NA 836 854 872 890
Deposits & Other Assets NA 80 52 17 18
Total Assets NA 2,118 1,969 1,842 1,733
Liabilities & Shareholders Equity 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 12 15 13 12
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 96 118 118 101
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 109 133 132 112
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 12 14 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,504 1,503 1,501 1,499
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 31 31 38
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,665 1,680 1,664 1,649
Shareholders Equity 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 62 31 12 2
Retained Earnings NA 398 261 167 91
Other Equity NA -7 -2 -1 -9
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 453 289 178 84
Total Liabilities & Shareholder's Equity NA 2,118 1,969 1,842 1,733
Total Common Equity 0 453 289 178 84
Shares Outstanding 127.20 127.20 127.20 127.00 132.10
Book Value Per Share 0.00 3.56 2.28 1.40 0.63